HDAC2 and urinary bladder carcinoma: Given the established role of HDACs in driving drug resistance across cancers and the status of cisplatin-based chemotherapy as the first-line treatment for advanced bladder cancer (BCa), we investigated the specific involvement of HDAC2 in cisplatin resistance.